Press coverage about Otonomy (NASDAQ:OTIC) has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.4809013791141 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several research firms have recently issued reports on OTIC. Zacks Investment Research cut shares of Otonomy from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $8.00 price objective on shares of Otonomy in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Otonomy currently has an average rating of “Hold” and an average target price of $9.15.
Otonomy (NASDAQ OTIC) traded down $0.25 during mid-day trading on Friday, hitting $5.85. 330,718 shares of the company were exchanged, compared to its average volume of 475,229. Otonomy has a 1 year low of $2.80 and a 1 year high of $21.15. The stock has a market capitalization of $185.06, a price-to-earnings ratio of -1.81 and a beta of 3.33.
Otonomy (NASDAQ:OTIC) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.15. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.43 million. The firm’s revenue for the quarter was down 12.8% on a year-over-year basis. sell-side analysts expect that Otonomy will post -2.88 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/13/otonomy-otic-earning-somewhat-favorable-news-coverage-analysis-shows.html.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.